Incremental Prognostic Implications of Brain Natriuretic Peptide, Cardiac Sympathetic Nerve Innervation, and Noncardiac Disorders in Patients with Heart Failure

Michifumi Kyuma, MD1; Tomoaki Nakata, MD, PhD2; Akiyoshi Hashimoto, MD, PhD1; Kazuhiko Nagao, MD, PhD2; Hisataka Sasaо, MD, PhD3; Toru Takahashi, MD1; Kazufumi Tsuchihashi, MD, PhD1; and Kazuaki Shimamoto, MD, PhD1

1Second Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan; 2Sapporo Cardiovascular Clinic, Sapporo, Japan; and 3Division of Cardiovascular Medicine, Hakodate Goryokaku Hospital, Hakodate, Japan

Plasma brain natriuretic peptide (BNP) level and cardiac autonomic function are closely related to prognosis in patients with heart failure. However, their correlation and incremental prognostic values in human heart failure are unclear. We sought to evaluate the correlation between BNP level and cardiac sympathetic innervation assessed by 123I-metaiodobenzylguanidine (123I-MIBG) and the prognostic value of combined assessment of risk factors for mortality in patients with heart failure. Methods: After conventional examinations and measurements of plasma BNP level and heart-to-mediastinum ratio (HMR) of cardiac 123I-MIBG activity, 158 patients with heart failure were prospectively followed with an endpoint of cardiac death for 16 mo. Results: Fifteen deaths due to pump failure and 2 sudden cardiac deaths were documented. Plasma BNP level correlated with HMR significantly but not so tightly (r = 0.33, P < 0.0001). Univariate analysis identified plasma BNP level, HMR, chronic renal dysfunction, diabetes mellitus, age, and use of nitrates as significant predictors of fatal pump failure, and multivariate Cox analysis showed that plasma BNP level was the most powerful predictor of cardiac death. Patients with both plasma BNP level of ≥172 pg/mL and late HMR of ≤1.74 had a greater annual rate of fatal pump failure than did those without (17.5%/y vs. 0%–3.9%/y, respectively). The hazard ratio of plasma BNP level (7.2) or cardiac 123I-MIBG activity (10.1) increased to 34.4 when both variables were used, and prevalence of fatal pump failure significantly increased from 22% to 62.5% when diabetes mellitus and chronic renal dysfunction were present with a higher plasma BNP level and low cardiac 123I-MIBG activity. Conclusion: Plasma BNP level is a stronger predictor than other risk factors for mortality in heart failure patients and is statistically significantly, but roughly, related to cardiac sympathetic nerve innervation. Impaired cardiac sympathetic nerve innervation and the presence of diabetes mellitus and chronic renal dys-

Although treatment with angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), or β-blockers has recently been established as a standard drug treatment for improving survival of patients with heart failure, the efficacy of this treatment appears to be limited, even in selected patients with heart failure: The overall reduction in mortality rate is estimated to be only 30%–40%. New approaches to further risk stratification of patients undergoing contemporary drug treatment who are at greater risk for cardiac death are, therefore, needed. Brain natriuretic peptide (BNP) is a powerful predictor of clinical outcomes and is a better marker of efficacy of drug treatment in patients with heart failure than are other neurohumoral factors and conventional clinical markers (1–4). Long-term prognosis of patients with heart failure is affected by various noncardiac background factors such as renal dysfunction (5), diabetes mellitus (6), and hypertension (7). On the other hand, it is well known that central and peripheral sympathetic nervous systems are augmented in patients with failing hearts, whereas myocardial content of norepinephrine is impaired. Cardiac sympathetic function per se has also been shown to have pathophysiologic and prognostic implications (6,8–13). We have characterized potent and incremental prognostic values of cardiac sympathetic function assessed by 123I-metaiodobenzylguanidine (123I-MIBG) in human heart failure (12,13). It is thought that sympathoinhibitory actions of natriuretic peptides di-
rectly or indirectly retrain sympathetic nervous system out-
flow in the myocardium as well as in peripheral tissues. Despite the clinical implications of BNP and cardiac symp-
thetic activity in patients with heart failure, their correla-
tion has not been determined, and incremental prognostic values of BNP on top of other determinants of clinical
outcome, including cardiac autonomic function and noncar-
diac diseases, have not been fully investigated.

This prospective study was designed to determine the
correlation between plasma BNP concentration and cardiac
sympathetic nerve function and the prognostic value of
plasma BNP concentration in patients with heart failure
under current medical treatment as well as to determine
whether combined assessment of these indices and other
diseased states, if identified, enables better risk stratification
for identification of patients at greater risk for cardiac death.

MATERIALS AND METHODS

Patient Population and Study Protocol

One hundred fifty-eight consecutive patients with congestive
heart failure of New York Heart Association (NYHA) functional
classes II–IV at entry (between 1999 and 2001) were enrolled.
The entry criteria for this study were as follows: (a) recent docu-
tmentation of symptomatic heart failure, including easy fatigability,
exertional dyspnea, palpitation and orthopnea, accompanying jug-
ular vein dilatation, moist rales, S3 gallop, peripheral edema,
and pulmonary congestion or cardiomegaly on a chest radiograph; (b)
measurement of plasma BNP level and cardiac MIBG scintigraphy
having been performed on the same day or within a few days’
time, after congestive heart failure had been stabilized by
appropriate medical therapy as recommended in recent guidelines
(14); (c) standard cardiac function tests using 2-dimensional echocardiography and radionuclide techniques having been performed
within 1 wk after 123I-MIBG imaging under stable general condi-
tions before discharge; (d) no indication for an invasive therapeutic
procedure, except for the use of an implantable cardioverter defi-
brillator (ICD) during the period of hospitalization; and (e) in-
formed consent for participation in the study based on the guide-
lines of the ethics committee of our hospital having been obtained
from the patient. The patients included 110 males and 48 females
with a mean age of 64 ± 13 y. Nineteen (12%) of the 158 patients
were at NYHA class I without any effort-induced symptom in
response to medical therapy after admission. In the remaining 139
patients, symptomatic heart failure was stabilized but persisted
(Table 1). The mean left ventricular ejection fraction (LVEF) was
41% ± 17%, and 54 (34%) of the patients had LVEF of <30% (Table 1).
The etiology of left heart failure was identified as ischemic heart disease in 45 (28%) of the patients and as nonis-
chemic cardiomyopathy in the remaining 113 (72%) patients.
Atrial fibrillation and ventricular tachycardia were documented in
63 (40%) and 46 (29%) of the patients, respectively. Chronic renal
dysfunction, hypertension, and diabetes mellitus were identified in
27 (17%), 14 (9%), and 45 (28%) of the patients, respectively.
Chronic renal dysfunction was defined as a persistent elevation in
serum creatinine concentration of ≥1.5 mg/mL (133 μmol/L) or as
a creatinine clearance of <50 mL/min. Diabetes mellitus was defined as an increased fasting plasma glucose concentration of
≥126 mg/dL (18.5 mmol/L), glycosylated hemoglobin (HbA1c) of
≥6.4%, or when patients undergo treatment with insulin or hypo-
TABLE 1
Clinical Backgrounds of 158 Patients and Comparison Between Survivors and Nonsurvivors

<table>
<thead>
<tr>
<th>Parameter</th>
<th>All patients (n = 158)</th>
<th>Survivors (n = 138)</th>
<th>Nonsurvivors (n = 20)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (M/F)</td>
<td>110/48</td>
<td>94/44</td>
<td>16/4</td>
<td>0.412</td>
</tr>
<tr>
<td>Age (y)</td>
<td>64 ± 13</td>
<td>63 ± 13</td>
<td>70 ± 12</td>
<td>0.025</td>
</tr>
<tr>
<td>NYHA functional class</td>
<td>2.4 ± 0.9</td>
<td>2.3 ± 0.8</td>
<td>3.0 ± 0.9</td>
<td>0.146</td>
</tr>
<tr>
<td>I/II (%)</td>
<td>19/78 (12/49)</td>
<td>18/73 (13/53)</td>
<td>1/5 (5/25)</td>
<td>0.022</td>
</tr>
<tr>
<td>III/IV (%)</td>
<td>39/22 (25/14)</td>
<td>31/16 (22/12)</td>
<td>8/6 (40/30)</td>
<td></td>
</tr>
<tr>
<td>LV end-diastolic dimension (mm)</td>
<td>57 ± 10</td>
<td>57 ± 10</td>
<td>59 ± 12</td>
<td>0.417</td>
</tr>
<tr>
<td>LVEF (%)</td>
<td>41 ± 17</td>
<td>42 ± 17</td>
<td>39 ± 17</td>
<td>0.462</td>
</tr>
<tr>
<td>≤30% (%)</td>
<td>54 (34)</td>
<td>45 (33)</td>
<td>9 (45)</td>
<td>0.401</td>
</tr>
<tr>
<td>Late HMR of 123I-MIBG activity</td>
<td>1.73 ± 0.37</td>
<td>1.75 ± 0.39</td>
<td>1.60 ± 0.21</td>
<td>0.095</td>
</tr>
<tr>
<td>Washout rate of 123I-MIBG activity (%)</td>
<td>36 ± 14</td>
<td>35 ± 13</td>
<td>38 ± 17</td>
<td>0.356</td>
</tr>
<tr>
<td>BNP (pg/mL)</td>
<td>353 ± 449</td>
<td>301 ± 400</td>
<td>714 ± 594</td>
<td>0.001</td>
</tr>
<tr>
<td>Underlying diagnosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ischemic (%)</td>
<td>45 (28)</td>
<td>36 (26)</td>
<td>9 (45)</td>
<td>0.137</td>
</tr>
<tr>
<td>Nonischemic (%)</td>
<td>113 (72)</td>
<td>102 (74)</td>
<td>11 (55)</td>
<td></td>
</tr>
<tr>
<td>Complicated diseases (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atrial fibrillation/flutter</td>
<td>63 (40)</td>
<td>54 (39)</td>
<td>9 (45)</td>
<td>0.797</td>
</tr>
<tr>
<td>Ventricular tachycardia</td>
<td>46 (29)</td>
<td>38 (28)</td>
<td>8 (40)</td>
<td>0.379</td>
</tr>
<tr>
<td>Hypertension</td>
<td>14 (9)</td>
<td>11 (8)</td>
<td>3 (15)</td>
<td>0.540</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>45 (28)</td>
<td>36 (26)</td>
<td>9 (45)</td>
<td>0.137</td>
</tr>
<tr>
<td>Chronic renal dysfunction</td>
<td>27 (17)</td>
<td>18 (13)</td>
<td>9 (45)</td>
<td>0.001</td>
</tr>
<tr>
<td>Concomitant medication</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diuretic (%)</td>
<td>106 (67)</td>
<td>89 (64)</td>
<td>17 (85)</td>
<td>0.117</td>
</tr>
<tr>
<td>Spironolactone (%)</td>
<td>61 (39)</td>
<td>52 (38)</td>
<td>9 (45)</td>
<td>0.702</td>
</tr>
<tr>
<td>Digitalis (%)</td>
<td>45 (28)</td>
<td>38 (28)</td>
<td>7 (35)</td>
<td>0.670</td>
</tr>
<tr>
<td>β-Blocker (%)</td>
<td>87 (55)</td>
<td>78 (57)</td>
<td>9 (45)</td>
<td>0.467</td>
</tr>
<tr>
<td>ACE-I (%)</td>
<td>59 (37)</td>
<td>54 (39)</td>
<td>5 (25)</td>
<td>0.330</td>
</tr>
<tr>
<td>ACE-I and/or ARB (%)</td>
<td>101 (64)</td>
<td>89 (64)</td>
<td>12 (60)</td>
<td>0.887</td>
</tr>
<tr>
<td>ACE-I, ARB, and/or β-blocker (%)</td>
<td>133 (84)</td>
<td>117 (85)</td>
<td>16 (80)</td>
<td>0.826</td>
</tr>
<tr>
<td>Nitrate (%)</td>
<td>39 (25)</td>
<td>29 (21)</td>
<td>10 (50)</td>
<td>0.011</td>
</tr>
<tr>
<td>Amiodarone (%)</td>
<td>17 (11)</td>
<td>15 (11)</td>
<td>2 (10)</td>
<td>0.788</td>
</tr>
<tr>
<td>ICD implanted (%)</td>
<td>12 (8)</td>
<td>12 (9)</td>
<td>0 (0)</td>
<td>0.357</td>
</tr>
<tr>
<td>Follow-up period (mo)</td>
<td>16 ± 9</td>
<td>17 ± 9</td>
<td>7 ± 8</td>
<td>0.001</td>
</tr>
</tbody>
</table>

LV = left ventricular.
Values are mean ± SD.

FIGURE 1. (A) A late cardiac planar 123I-MIBG image obtained from a 60-y-old female with congestive heart failure who had fatal pump failure. She had a persistently depressed LVEF (16%) and a highly increased plasma BNP level (1,070 pg/mL). Her late HMR (1.49) was markedly reduced. (B) A late cardiac planar 123I-MIBG image obtained from a 66-y-old male with congestive heart failure who survived. In response to drug therapy, he has an LVEF of 62%, a plasma BNP level of 76 pg/mL, and a normally preserved late HMR (2.14) at discharge. The box and oval indicate regions of interest on the upper mediastinal and cardiac areas, respectively, for calculation of the HMR of 123I-MIBG activity.
tes mellitus, chronic renal dysfunction, tachyarrhythmias), LVEF, percentage of fractional shortening, left ventricular end-diastolic and end-systolic dimensions, plasma BNP level, medications used, early and late HMR, and its washout rate. Correlations between 2 continuous variables were analyzed by using linear regression analysis. Univariate and multivariate analyses with the Cox proportional hazards model were used to identify significant predictors of death. The Kaplan–Meier method was used to determine the time-dependent cumulative survival rate. Comparison of mean values between 2 groups was made using the unpaired Student t test, and prevalence was compared using the χ² test. Survival curves were compared using the log rank test. Statistical potentials of selected independent predictors in univariate analysis were followed by multivariate analysis using the Wald χ² and the Cox proportional hazards model. P < 0.05 was considered to be statistically significant. These analyses were performed using a computer software program, the SPSS statistical program package (SPSS version 11.0; SPSS Inc.).

RESULTS

Patient Characteristics and Outcomes

During 16 mo, 17 cardiac deaths and 3 noncardiac deaths were documented: 15 patients died from pump failure, 2 patients had sudden cardiac death, 1 patient died perioperatively when noncardiac surgery was performed, 1 died from acute pneumonia, and 1 died from a malignant tumor. Table 1 shows the clinical backgrounds of the patients who survived and those who died. The nonsurvivors had a significantly advanced age, greater NYHA functional class, greater plasma BNP concentration, and greater prevalence of chronic renal dysfunction and nitrate use compared with the survivors. There were, however, no significant differences in other variables, including cardiac function, scintigraphic data, underlying cardiac and noncardiac diseases, and other medications. ICD discharge was documented in 3 of the 12 patients in whom an ICD had been used.

Figure 1 shows typical late 123I-MIBG images. Despite aggressive medical treatment, a 60-y-old female with a persistently depressed LVEF (16%), a greatly increased plasma BNP level (1,070 pg/mL), and a markedly reduced 123I-MIBG HMR (1.49) at discharge had fatal pump failure.

A 66-y-old male who had an LVEF of 62%, a plasma BNP level of 76 pg/mL, and a well-preserved 123I-MIBG ratio (2.14) showed a good response to drug treatment, resulting in good prognosis.

Correlations of Plasma BNP Level with Cardiac Sympathetic Innervation and LVEF

The plasma BNP level showed significant inverse correlations with the cardiac 123I-MIBG activity (late HMR) (r = 0.330, P < 0.0001) and with the LVEF (r = 0.192, P = 0.0150) (Fig. 2). Although the correlations were still statistically significant without use of a logarithm, the data were widely distributed and the inverse correlations are rough (r = 0.288, P = 0.0002 for late HMR and r = 0.190, P = 0.0168 for LVEF).

Determinants of Fatal Cardiac Events in Univariate and Multivariate Analyses

Univariate analysis identified the plasma BNP level, chronic renal dysfunction, age, cardiac 123I-MIBG activity (late HMR), use of nitrates, and diabetes mellitus as significant predictors of death due to pump failure (Table 2). Multivariate Cox proportional hazards regression analysis using these significant predictors showed that the plasma BNP level was an independent powerful determinant of fatal pump failure: Wald χ² values and hazard ratios were 5.0916 and 1.0010, respectively (P = 0.02404) (Table 2).

Event Curve Analysis and Event Rates

Patients were classified into 2 groups using 2 thresholds: a plasma BNP level of 172 pg/mL, which was the median value of plasma BNP levels in this study, and a cardiac 123I-MIBG activity (late HMR) of 1.74, which was the threshold identified in our previous study (12). The mortality rate due to pump failure was significantly higher in patients with a higher plasma BNP level (log rank = 9.50, P = 0.002, hazard ratio = 7.2, and 95% confidence interval = 1.6–32.1) or a lower cardiac 123I-MIBG activity (log rank = 7.70, P = 0.006, hazard ratio = 10.1, and 95% confidence interval = 1.3–77.0) than those of other patients (Fig. 3A). Likewise, when 127 patients with an LVEF of

![FIGURE 2. Correlations of the plasma BNP level with the cardiac 123I-MIBG activity quantified as late HMR (A) and LVEF (B). The inverse correlations between them are statistically significant but weak.](image)
<50% were considered, patients with a higher plasma BNP level or a lower cardiac 123I-MIBG activity showed significantly greater survival rates than each counterpart (Fig. 3B). When patients were divided into 4 groups using both thresholds of the plasma BNP level and the cardiac 123I-MIBG activity, the group of patients with a plasma BNP level of <172 pg/mL and a late HMR of <1.74 had a significantly higher prevalence of fatal pump failure (21.8%; χ² = 11.975, P < 0.001) than did the other groups (0%–5.4%) and an apparently greater annual rate of fatal pump failure (17.5%/y) than did the other groups (0%–3.9%/y) (Fig. 4A). When 127 patients with an LVEF of <50% were considered, the patient group with a higher plasma BNP level or a lower cardiac 123I-MIBG activity showed a significantly (P < 0.05) greater prevalence (22.2%) and an annual rate of fatal pump failure (18.4%/y) than did the other groups (Fig. 4B).

### Incremental Prognostic Values in Combination of BNP Level and Other Variables

Figure 5 shows incremental prognostic values of combined assessment of the plasma BNP level, cardiac 123I-MIBG activity, and other factors such as chronic renal dysfunction, age, cardiac 123I-MIBG activity, nitrate, diabetes mellitus, and age. The table below presents the univariate and multivariate analyses for predicting cardiac death due to pump failure:

<table>
<thead>
<tr>
<th>Variable</th>
<th>Wald x²</th>
<th>Hazard ratio</th>
<th>95% CI of hazard ratio</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Univariate analysis</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BNP</td>
<td>14.0353</td>
<td>1.0001</td>
<td>1.0000–1.0021</td>
<td>0.00018</td>
</tr>
<tr>
<td>Chronic renal dysfunction</td>
<td>9.0347</td>
<td>4.7697</td>
<td>1.7221–13.2105</td>
<td>0.00265</td>
</tr>
<tr>
<td>Age</td>
<td>7.1966</td>
<td>1.0742</td>
<td>1.0195–1.1319</td>
<td>0.00730</td>
</tr>
<tr>
<td>Cardiac 123I-MIBG activity (late HMR)</td>
<td>4.8351</td>
<td>0.1426</td>
<td>0.0251–0.8093</td>
<td>0.02789</td>
</tr>
<tr>
<td>Nitrate</td>
<td>4.8213</td>
<td>3.1256</td>
<td>1.1302–8.6440</td>
<td>0.02811</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>4.0436</td>
<td>2.8446</td>
<td>1.0268–7.8806</td>
<td>0.04434</td>
</tr>
<tr>
<td>Chronic renal dysfunction</td>
<td>0.2434</td>
<td>1.3716</td>
<td>0.3910–4.8116</td>
<td>NS</td>
</tr>
</tbody>
</table>

| **Multivariate analysis**       |         |              |                        |      |
| BNP                             | 5.0916  | 1.0010       | 1.0001–1.0019          | 0.02404 |
| Age                             | 3.4327  | 1.0546       | 0.9969–1.1157          | NS   |
| Cardiac 123I-MIBG activity (late HMR) | 1.5205  | 0.3202       | 0.0524–1.9566          | NS   |
| Nitrate                         | 1.1320  | 1.8311       | 0.6008–5.5804          | NS   |
| Diabetes mellitus               | 1.0694  | 1.8527       | 0.5758–5.9617          | NS   |
| Chronic renal dysfunction       | 0.0742  | 1.3716       | 0.3910–4.8116          | NS   |

CI = confidence interval; NS = no significance.

---

**FIGURE 3.** Kaplan–Meier event (fatal pump failure)-free curves when patients were stratified into 2 groups using the thresholds of a plasma BNP level of 172 pg/mL and a late HMR of 1.74. The group of patients with plasma BNP levels of <172 pg/mL (left) or HMRs of >1.74 (right) had a significantly lower event rate than did each counterpart not only when all 158 patients were considered (A) but also when 127 patients who had an LVEF of <50% were considered for this analysis (B).
MIBG activity, diabetes mellitus, or chronic renal dysfunction, all of which were identified as significant predictors of fatal pump failure in univariate analysis (Table 2). The hazard ratio of the plasma BNP level (7.2) or the cardiac 123I-MIBG activity (10.1) increased to 34.4 when both variables were used, but no further improvement was observed in other combinations. The rate of fatal pump failure increased significantly from 22% to 62.5% when high plasma BNP and low cardiac 123I-MIBG activity levels accompanied both diabetes mellitus and chronic renal dysfunction.

**DISCUSSION**

The present results show that survival of patients with heart failure is related to depressed cardiac sympathetic activity and elevated BNP level and that combined assessment of these indices can improve risk stratification of patients at greater risk for pump failure death. Plasma BNP level increases in relation to interplay between hemodynamic alterations and cardiac function but is affected by age or right ventricular conditions. Augmented activities of central and peripheral sympathetic nervous systems (15) have potential deleterious effects on the cardiovascular system, whereas the myocardial content of norepinephrine is reduced in failing hearts (8). This finding is consistent with the observation of markedly depressed cardiac 123I-MIBG activity in failing hearts because the level of cardiac 123I-MIBG activity is related to the myocardial epinephrine content (16). The inverse correlation between the plasma

**FIGURE 4.** Comparison of prevalence (left) and annual rate of fatal pump failure (right) when patients were classified into 4 groups using the thresholds of a plasma BNP level of 172 pg/mL and an HMR of 1.74. The group of patients who had both a plasma BNP level of ≥172 pg/mL and an HMR of ≥1.74 had significantly greater event rates than those of the other 3 groups not only when all 158 patients were considered (A) but also when 127 patients who had an LVEF of <50% were considered for this analysis (B). *P < 0.05 vs. the other 3 groups.

**FIGURE 5.** Incremental prognostic values of combined assessment of the plasma BNP level, the cardiac 123I-MIBG activity, diabetes mellitus (DM), or chronic renal dysfunction (CRD), all of which are significant predictors of fatal pump failure in univariate analysis (Table 2). Hazard ratios ([]} for fatal pump failure increased to 34.413 when both the plasma BNP level and the cardiac 123I-MIBG activity were used, but no further improvement was achieved in any other combination. On the other hand, the greatest prevalence (62.5%) of fatal pump failure (]]) was observed when all of these variables were used.
BNP level and the cardiac sympathetic activity found in this study can be explained by their roles in heart failure. BNP is a slowly responding but powerful hormone in relation to the need for overload reduction in heart failure. Augmentation of central and peripheral functions of autonomic nervous systems, as an initial compensatory mechanism, makes sympathetic innervation in the myocardium exhausted and impaired during a long-term process, eventually leading to lethal outcome. This is probably because increases in circulating catecholamine levels and sympathetic outflow have deteriorating effects on the myocardium (17), because production of neurotransmitters at nerve terminals is reduced (18) and because depletion of high-energy phosphate at nerve endings impairs ion balance and autonomic functions (19). Recent investigations have shown that natriuretic peptides modulate systemic and cardiac autonomic nervous systems through a central neural action, by stimulating arterial and cardiac baroreceptor afferent nerve terminals or by inhibiting sympathetic ganglionic neurotransmission (20–22) even in a physiologic range (22). The correlation between the plasma BNP level and the cardiac sympathetic activity was statistically significant but not so strong in this study, suggesting differences in their roles in the heart failure process and the existence of confounding factors that modify hemodynamic conditions, stimulation of BNP synthesis, and cardiac sympathetic nerve functions. A significant but not strong correlation between the plasma BNP level and the LVEF is probably because LVEF is affected by hemodynamic conditions and sympathetic activity and because the natriuretic peptide level is related not only to systolic dysfunction but also to diastolic dysfunction (23). These findings support the rationale of combined use of these neuronal and humoral factors for risk stratification of patients with heart failure at high risk for lethal outcomes.

There are several known clinical backgrounds or noncardiac diseased states that affect long-term prognosis of patients with heart failure (5–7,24). The plasma BNP level was the most powerful prognostic marker among the variables examined in multivariate Cox analysis. It should, however, be noted that risk for fatal pump failure increases significantly when both diabetes mellitus and chronic renal dysfunction are present in patients with heart failure in whom the plasma BNP level is elevated and the cardiac 123I-MIBG activity is impaired, suggesting incremental prognostic implications of the diabetic state and chronically impaired kidney function in patients with heart failure. Earlier studies (5,6,25–29) also showed that diabetic mellitus and renal dysfunction are likely to be risk factors for mortality in patients with left ventricular dysfunction. Although the precise mechanisms of adverse effects of these conditions were not determined in this study, there are some possible explanations. Both diabetic mellitus and renal dysfunction at an advanced stage impair the function of the autonomic nervous system in the myocardium independent of complicated structural heart disease (30,31), resulting in impairment of cardiac functional reserve, regulation of vascular tone, and electrophysiological stability. In addition, a diabetic state impairs endothelial function in the coronary artery and augments epicardial coronary sclerosis, interstitial fibrosis, and intracellular metabolic alterations in failing hearts, all of which possibly lead to further impairment of cardiac diastolic and systolic performances and to lethal arrhythmias (25–27). Although reduced kidney function is a powerful independent predictor of mortality in patients with advanced heart failure, it remains controversial whether impaired renal function is associated with low cardiac output or with cardiac risk factors for mortality, such as low LVEF and high NYHA functional class (5,28,29). Renal dysfunction may be related to systemic risk factors for mortality, such as electrolyte (sodium and potassium) imbalance, hyperfibrinogenemia, increased C-reactive protein levels, overloaded conditions, and anemia (5,24).

In this study, patients underwent standard drug treatment for heart failure (14), including treatment with ACE inhibitors, ARBs, and β-blockers; 133 (84%) of the patients were treated with at least one of these drugs, but these drugs were not used for treatment of the remaining 25 (16%) patients because of adverse effects, depressed heart rate, or low systolic blood pressure. BNP and cardiac 123I-MIBG values were measured under conditions stabilized by the drug treatment because both of these values can alter during an early stage of heart failure and pharmacologic introduction and because this study aimed to evaluate long-term prognosis using data obtained at discharge. It is notable that combined assessment of the plasma BNP level and the cardiac sympathetic innervation enabled more accurate identification of patients at greater risk who were undergoing the standard drug treatment for heart failure. Because both BNP and 123I-MIBG data may have altered during a long-term period or due to progression of heart failure (32–36), it is necessary to determine the appropriate timing and appropriate interval for measurements of the plasma BNP level and the cardiac 123I-MIBG activity during the clinical course of heart failure for more accurate prediction of the long-term prognosis.

Another important clinical issue is whether the markers used here are reliable predictors of sudden death in patients with heart failure. There is no established method for predicting sudden lethal events, probably because of the many triggers involved (37). Berger et al. (33) recently showed the possibility of the plasma BNP level predicting sudden death in patients with an LVEF of ≈35%. Although the statistical powers of the plasma BNP level and the cardiac 123I-MIBG activity were maintained when 2 sudden cardiac deaths and 3 ICD discharges observed in this study were included in the analysis, the small number of episodes made it difficult to draw a definitive conclusion. Our recent study has demonstrated that combined data on cardiac 123I-MIBG activity and heart rate variability improves prediction of ICD shock due to lethal arrhythmias (38). This preliminary result suggests that depressed functions of central and cardiac autonomic nervous systems are responsible for sudden...
lithal events and that combined assessment of these indices is useful for the prediction of and management of heart failure patients at high risk for sudden cardiac death.

Cardiac 123I-MIBG imaging enables assessment of the presynaptic function of the cardiac sympathetic nervous system but not the postsynaptic function. In failing hearts, β-adrenoceptor function is downregulated, whereas supersensitivity of adrenoceptor function is observed when cardiac sympathetic presynaptic innervation is impaired (39). The interaction between pre- and postsynaptic functions in failing human hearts must be determined. The patients enrolled in this study had congestive heart failure, but 31 (20%) of the patients had an LVEF of ≥50% at convalescence. In particular, 16 (10%) patients with an LVEF of ≥65% had left ventricular hypertrophy and diastolic dysfunction on 2-dimensional echocardiography. Heart failure with preserved systolic function is observed in roughly one third of patients with heart failure, probably due to diastolic dysfunction (40). These findings suggest that assessment of the cardiac sympathetic innervation and the BNP level is useful for identifying heart failure patients who have preserved systolic function but impaired diastolic function and are at high risk for cardiac death. A recently reported rapid assay of the BNP level is a promising method for screening, early diagnosis, and monitoring of patients with suspected or known heart failure. Despite the limited availability of cardiac 123I-MIBG imaging, the noninvasive and quantitative features can contribute to further risk assessment of heart failure patients who are identified to be at high risk for cardiac death by the plasma BNP level and other variables. Finally, the present findings indicate the need for planning a larger prospective multicenter study to establish a new diagnostic strategy using the plasma BNP level, cardiac sympathetic nerve activity, and other clinical markers.

CONCLUSION

The plasma BNP level is inversely related to cardiac sympathetic nerve innervation and is a more powerful prognostic marker than other factors for mortality in patients with congestive heart failure who have undergone contemporary drug therapy. Impaired cardiac sympathetic nerve innervation and the presence of diabetes mellitus and chronic renal dysfunction, however, increase the risk for lethal cardiac events in patients with heart failure and increased plasma BNP concentration. Thus, combined assessment of the plasma BNP level, cardiac sympathetic innervation, and noncardiac diseases such as diabetic state and impaired kidney function enables better identification of patients at greater risk for cardiac death.

ACKNOWLEDGMENTS

The authors thank the staffs of the Cardiology Department and Division of Nuclear Medicine, Sapporo Medical University School of Medicine, Sapporo; the Cardiovascular Clinic, Sapporo; and the Division of Cardiovascular Medicine, Hakodate Goryokaku Hospital, Hakodate, for their cooperation in clinical services.

REFERENCES


